AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22608584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral iliohypogastric and ilioinguinal nerve blocks with 24 mL of 0.5% bupivacaine
Number of subjects: 34
Study 22608584 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 34
Study 20581162 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal cavity spray of benzydamine hydrochloride (BH) and distilled water on the ET cuff (Group A)
Number of subjects: 380
Study 20581162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oropharyngeal cavity and ET cuff received BH spray (Group B)
Number of subjects: 380
Study 20581162 — intervention group
Group type: EXPERIMENTAL
Intervention: ET cuff received BH spray, oropharyngeal cavity received distilled water (Group C)
Number of subjects: 380
Study 20581162 — intervention group
Group type: COMPARATOR
Intervention: Distilled water sprayed on both ET tube and oropharyngeal cavity (Group D)
Number of subjects: 380
Study 18035203 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (generic soft-gelatin capsule of cyclosporin A microemulsion, 100 mg)
Number of subjects: 36
Study 18035203 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (branded soft-gelatin capsule of cyclosporin A microemulsion, 100 mg)
Number of subjects: 36
Study 19253780 — intervention group
Group type: COMPARATOR
Intervention: Hearing aids in omnidirectional microphone mode
Number of subjects: 14
Study 19253780 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids with noise reduction (NR) algorithm and directional microphones
Number of subjects: 14
Study 19253780 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplification (hearing aids)
Number of subjects: 14
Study 15232503 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow
Number of subjects: 19
Study 15232503 — intervention group
Group type: COMPARATOR
Intervention: Non-pulsatile flow
Number of subjects: 19
Study 11735786 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy (first or second AGIS intervention)
Number of subjects: 591
Study 11735786 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy without complications
Number of subjects: 591
Study 11735786 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with complications
Number of subjects: 591
Study 11735786 — intervention group
Group type: EXPERIMENTAL
Intervention: Marked inflammation as a postoperative complication
Number of subjects: 591
Study 11735786 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat anterior chamber as a postoperative complication
Number of subjects: 591
Study 11735786 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at study entry
Number of subjects: 591
Study 11735786 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 591
Study 9240286 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute form of SF-36 Health Survey (one-week recall)
Number of subjects: 142
Study 9240286 — intervention group
Group type: COMPARATOR
Intervention: Standard form of SF-36 Health Survey (four-week recall)
Number of subjects: 142
Study 8370085 — intervention group
Group type: EXPERIMENTAL
Intervention: Floating (F) hydrophilic matrix capsules
Number of subjects: 0
Study 8370085 — intervention group
Group type: COMPARATOR
Intervention: Nonfloating (NF) hydrophilic matrix capsules
Number of subjects: 0
Study 3535474 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg orally twice a day (or 400 mg if weight > 80 kg) from 36 hours after surgery until discharge (usually on the seventh day)
Number of subjects: 100
Study 3535474 — intervention group
Group type: COMPARATOR
Intervention: Control group (no beta-blocking drugs)
Number of subjects: 100
Study 11522432 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (48 smoking alcoholics)
Number of subjects: 63
Study 11522432 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking (15 nonsmoking alcoholics)
Number of subjects: 63
Study 31136283 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Trimethylamine N-Oxide Concentration
Number of subjects: 0
Study 31136283 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline CSPPT participants who did not develop stroke during follow-up)
Number of subjects: 0
Study 29044968 — intervention group
Group type: EXPERIMENTAL
Intervention: DUT‐TAM FDC therapy (dutasteride 0.5 mg and tamsulosin 0.4 mg)
Number of subjects: 489
Study 29044968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 27154875 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit training (1 hour, 2 days per week, during 8 weeks)
Number of subjects: 38
Study 27154875 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance exercises
Number of subjects: 38
Study 24520784 — intervention group
Group type: EXPERIMENTAL
Intervention: qi benefiting stasis removing method (QBSRM)
Number of subjects: 40
Study 24520784 — intervention group
Group type: COMPARATOR
Intervention: Routine Western therapy (Control)
Number of subjects: 40
Study 22616853 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of controlled-release melatonin and cognitive-behavioural therapy
Number of subjects: 160
Study 22616853 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release melatonin
Number of subjects: 160
Study 22616853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 160
Study 22616853 — intervention group
Group type: COMPARATOR
Intervention: Placebo drug treatment
Number of subjects: 160
Study 22616853 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment group
Number of subjects: 160
Study 19705134 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine, 1 mg QD for 2 months
Number of subjects: 60
Study 19705134 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 60
Study 18029492 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated juice powder concentrate (JPC)
Number of subjects: 41
Study 18029492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15702262 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 98
Study 15702262 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility training
Number of subjects: 98
Study 15702262 — intervention group
Group type: COMPARATOR
Intervention: General stretching
Number of subjects: 98
Study 12236606 — intervention group
Group type: EXPERIMENTAL
Intervention: Drama-group therapy
Number of subjects: 122
Study 12236606 — intervention group
Group type: COMPARATOR
Intervention: Curriculum-studies control
Number of subjects: 122
Study 12236606 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 122
Study 10426340 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (3 times per week for 6 months) in group A
Number of subjects: 60
Study 10426340 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal oxygen consumption improvement in group A
Number of subjects: 60
Study 10426340 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing duration improvement in group A
Number of subjects: 60
Study 10426340 — intervention group
Group type: COMPARATOR
Intervention: Control group B (untrained hemodialysis patients)
Number of subjects: 60
Study 10426340 — intervention group
Group type: COMPARATOR
Intervention: Control group C (nonuremic sedentary persons)
Number of subjects: 60
Study 7769058 — intervention group
Group type: EXPERIMENTAL
Intervention: Normegon
Number of subjects: 158
Study 7769058 — intervention group
Group type: COMPARATOR
Intervention: Metrodin
Number of subjects: 158
Study 7769058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study 2186647 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaveretum and scopolamine
Number of subjects: 50
Study 2186647 — intervention group
Group type: COMPARATOR
Intervention: Temazepam
Number of subjects: 50
Study 116373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 2, 3, or 4 g with or without 1 g probenecid, administered as single daily doses for three days
Number of subjects: 90
Study 116373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 3 or 4 g
Number of subjects: 90
Study 30264170 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration during exercise using water (H1)
Number of subjects: 20
Study 30264170 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration during exercise using an isotonic sports drink (H2)
Number of subjects: 20
Study 30264170 — intervention group
Group type: COMPARATOR
Intervention: No rehydration during exercise (NH1)
Number of subjects: 20
Study 30264170 — intervention group
Group type: COMPARATOR
Intervention: No rehydration during exercise (NH2)
Number of subjects: 20
Study 29614468 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover foot (Össur Cheetah Xplore)
Number of subjects: 27
Study 29614468 — intervention group
Group type: COMPARATOR
Intervention: Energy storing foot (Össur Variflex)
Number of subjects: 27
Study 26746850 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol solution (OMS)
Number of subjects: 481
Study 26746850 — intervention group
Group type: COMPARATOR
Intervention: Vaginal dinoprostone
Number of subjects: 481
Study 25257907 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed video (HSV)
Number of subjects: 7
Study 25257907 — intervention group
Group type: COMPARATOR
Intervention: Videostroboscopy (VS)
Number of subjects: 7
Study 22288893 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (DRO) 2.5 mg twice per day for 2 days
Number of subjects: 36
Study 22288893 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (DRO) 5 mg twice per day for 2 days
Number of subjects: 36
Study 22288893 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) twice per day for 2 days
Number of subjects: 36
Study 22288893 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (DRO)
Number of subjects: 36
Study 20615252 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical spinal decompression via the DRX9000 for 6 weeks
Number of subjects: 30
Study 17394959 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus N-acetylcysteine (N-AC) infusion started just before contrast injection and continued for 12 h after PCI
Number of subjects: 111
Study 17394959 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration protocol consisting of intravenous isotonic saline for 12 h after PCI
Number of subjects: 111
Study 15637527 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg daily for 6 days)
Number of subjects: 12
Study 15637527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg daily for 6 days)
Number of subjects: 12
Study 15637527 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (2000 mg daily for 6 days)
Number of subjects: 12
Study 12712059 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused teamwork (TW) intervention
Number of subjects: 100
Study 12712059 — intervention group
Group type: COMPARATOR
Intervention: Standard multidisciplinary diabetes care (SC)
Number of subjects: 100
Study 10986827 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 percent carbamide peroxide (CP)
Number of subjects: 24
Study 10986827 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 percent hydrogen peroxide (HP)
Number of subjects: 24
Study 8795770 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 33
Study 8795770 — intervention group
Group type: COMPARATOR
Intervention: 1.0% carteolol
Number of subjects: 33
Study 8795770 — intervention group
Group type: COMPARATOR
Intervention: 2.0% carteolol
Number of subjects: 33
Study 1636805 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute plus maintenance treatment with imipramine (18 months)
Number of subjects: 30
Study 1636805 — intervention group
Group type: COMPARATOR
Intervention: Acute treatment with imipramine (6 months)
Number of subjects: 30
Study 6394778 — intervention group
Group type: EXPERIMENTAL
Intervention: 45% BCAA enriched (low leucine) amino acid solution
Number of subjects: 25
Study 6394778 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% BCAA amino acid solution
Number of subjects: 25
Study 6394778 — intervention group
Group type: EXPERIMENTAL
Intervention: 45% BCAA enriched (high leucine) amino acid solution
Number of subjects: 25
Study 6394778 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in water (control)
Number of subjects: 25
Study 31455015 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality experience of partly open green space
Number of subjects: 120
Study 31455015 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality experience of closed green space
Number of subjects: 120
Study 31455015 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality experience of blue space and partly closed green space
Number of subjects: 120
Study 31455015 — intervention group
Group type: EXPERIMENTAL
Intervention: Closing eyes for relaxation
Number of subjects: 120
Study 31455015 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality experience of six environmental types
Number of subjects: 120
Study 31455015 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for natural environments
Number of subjects: 120
Study 30012175 — intervention group
Group type: EXPERIMENTAL
Intervention: exergaming + a-tDCS
Number of subjects: 24
Study 30012175 — intervention group
Group type: COMPARATOR
Intervention: exergaming + sham a-tDCS
Number of subjects: 24
Study 30012175 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 24
Study 26351393 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal fistula plug (AFP) insertion
Number of subjects: 106
Study 26351393 — intervention group
Group type: COMPARATOR
Intervention: Seton removal (control group)
Number of subjects: 106
Study 24918122 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols claims (disease risk reduction claim, function claim, nutrient content claim)
Number of subjects: 1431
Study 24918122 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat fibre claims (three claims related to OF)
Number of subjects: 1431
Study 24918122 — intervention group
Group type: COMPARATOR
Intervention: Taste great claim (control)
Number of subjects: 1431
Study 22856593 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg by mouth twice a day for 7 days)
Number of subjects: 0
Study 22856593 — intervention group
Group type: COMPARATOR
Intervention: Placebo (by mouth, same dosage and duration as zinc)
Number of subjects: 0
Study 20216360 — intervention group
Group type: EXPERIMENTAL
Intervention: CR enhanced by SMT (stress management training) including relaxation training, cognitive restructuring, communication skills, and problem solving
Number of subjects: 150
Study 20216360 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise-based CR
Number of subjects: 150
Study 17921373 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber cereal (HF; 33 g insoluble fiber)
Number of subjects: 0
Study 17921373 — intervention group
Group type: COMPARATOR
Intervention: White bread (WB)
Number of subjects: 0
Study 17921373 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber cereal (LF)
Number of subjects: 0
Study 17921373 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 0
Study 16258291 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral breast reduction (BBR) surgery
Number of subjects: 0
Study 16258291 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 0
Study 12195689 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild electrical stimulation of the calf
Number of subjects: 49
Study 12195689 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild electrical stimulation of the plantar muscles
Number of subjects: 49
Study 12195689 — intervention group
Group type: COMPARATOR
Intervention: Non-stimulated lower extremity
Number of subjects: 49
Study 9736552 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) 70 mg in fasting state
Number of subjects: 15
Study 9736552 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) 70 mg 1 hour before a meal
Number of subjects: 15
Study 9736552 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) 70 mg 5 minutes after a high-fat breakfast
Number of subjects: 15
Study 7802178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 microgram.kg‐1
Number of subjects: 90
Study 7802178 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 20 micrograms.kg‐1
Number of subjects: 90
Study 7802178 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 90
Study 3055929 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein
Number of subjects: 12
Study 3055929 — intervention group
Group type: EXPERIMENTAL
Intervention: High Sucrose
Number of subjects: 12
Study 3055929 — intervention group
Group type: EXPERIMENTAL
Intervention: High Starch
Number of subjects: 12
Study 3055929 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 30998531 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101
Number of subjects: 0
Study 30998531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29466361 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial fat gain (EF gain) group (n = 65)
Number of subjects: 98
Study 29466361 — intervention group
Group type: COMPARATOR
Intervention: Epicardial fat decrease group (n = 33)
Number of subjects: 98
Study 29466361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EF gain and EF decrease)
Number of subjects: 98
Study 26909845 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape intake of 50 g/day
Number of subjects: 0
Study 26909845 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape intake of 100 g/day
Number of subjects: 0
Study 26909845 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape intake of 150 g/day
Number of subjects: 0
Study 26909845 — intervention group
Group type: COMPARATOR
Intervention: 0 g/day of grapes (control)
Number of subjects: 0
Study 25259781 — intervention group
Group type: EXPERIMENTAL
Intervention: Health educator (HE) intervention in the intervention group (IG)
Number of subjects: 165
Study 25259781 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 165
Study 25259781 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports participation
Number of subjects: 165
Study 22180445 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic neuropsychological approach
Number of subjects: 70
Study 22180445 — intervention group
Group type: COMPARATOR
Intervention: Conventional (functional) dressing practice
Number of subjects: 70
Study 21143878 — intervention group
Group type: COMPARATOR
Intervention: GTP (500 mg GTP/day)
Number of subjects: 171
Study 21143878 — intervention group
Group type: COMPARATOR
Intervention: TC exercise (60 min/session, 3 sessions/week)
Number of subjects: 171
Study 21143878 — intervention group
Group type: EXPERIMENTAL
Intervention: GTP + TC
Number of subjects: 171
Study 21143878 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo + TC
Number of subjects: 171
Study 21143878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 17275908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal 10% C3F8 infusion at the end of surgery
Number of subjects: 61
Study 17275908 — intervention group
Group type: COMPARATOR
Intervention: No intravitreal gas (Control)
Number of subjects: 61
Study 16225724 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 160
Study 16225724 — intervention group
Group type: COMPARATOR
Intervention: Propofol anaesthesia
Number of subjects: 160
Study 11898722 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin conventional therapy: 125 mg 3 times a day for 16 days
Number of subjects: 30
Study 11898722 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin chronotherapy: 125 mg once a day for 16 days at 22 p.m.
Number of subjects: 30
Study 10681809 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan treatment for 2 months
Number of subjects: 44
Study 10681809 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan in vitro
Number of subjects: 44
Study 7655202 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin sodium (+H)
Number of subjects: 72
Study 7655202 — intervention group
Group type: COMPARATOR
Intervention: No heparin (-H)
Number of subjects: 72
Study 2683835 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 57
Study 2683835 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 57
Study 9963 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethyldiazepam (nordiazepam) 5 mg
Number of subjects: 6
Study 9963 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethyldiazepam (nordiazepam) 10 mg
Number of subjects: 6
Study 9963 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium clorazepate 15 mg
Number of subjects: 6
Study 7244391 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical and rehabilitative therapy
Number of subjects: 51
Study 7244391 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 51
Study 31094793 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume/high concentration (LVHC) - 0.1 mL·kg of 0.4% levobupivacaine
Number of subjects: 70
Study 31094793 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume/low concentration (HVLC) - 0.2 mL·kg of 0.2% levobupivacaine
Number of subjects: 70
Study 31094793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LVHC and HVLC)
Number of subjects: 70
Study 28931169 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle educational package including face‐to‐face, phone and SMS counseling and a booklet in addition to routine postpartum training
Number of subjects: 220
Study 28931169 — intervention group
Group type: COMPARATOR
Intervention: Routine postpartum training
Number of subjects: 220
Study 26274346 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion to control blood glucose (normoglycemia 80-110 mg/dL)
Number of subjects: 405
Study 26274346 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemia (control group)
Number of subjects: 405
Study 26274346 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion to control blood glucose (normoglycemia) in critically ill rabbits
Number of subjects: 405
Study 26274346 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemia in critically ill rabbits (control group)
Number of subjects: 405